Details of the Drug

General Information of Drug (ID: DMZXF05)

Drug Name

GTx-024

Synonyms

(R)-Ostarine; 1132656-73-5; (2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide; C19H14F3N3O3; 841205-47-8 pound not1202044-20-9; SCHEMBL2197534; CHEBI:94527; DTXSID70649384; BCPP000135; AOB87717; ZINC35793633; BCP9001038; NCGC00408913-01; AS-17044; FT-0673314; Y0247; 370C134; I06-2154; BRD-K16621777-001-01-9; (R)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide

Indication

Disease Entry	ICD 11	Status	REF
Muscle atrophy	FB32.Y	Phase 3	[1]
Breast cancer	2C60-2C65	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H14F3N3O3
Canonical SMILES: CC(COC1=CC=C(C=C1)C#N)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
InChI: 1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1
InChIKey: JNGVJMBLXIUVRD-SFHVURJKSA-N

Cross-matching ID

PubChem CID: 11326715
CAS Number: 841205-47-8
TTD ID: D0NE3W

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT01355497) Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)